Cymbalta FDA Approval History
FDA Approved: Yes (First approved August 3, 2004)
Brand name: Cymbalta
Generic name: duloxetine
Dosage form: Delayed-Release Capsules
Company: Eli Lilly and Company
Treatment for: Neuropathic Pain, Pain, Osteoarthritis, Generalized Anxiety Disorder, Depression, Fibromyalgia, Diabetic Kidney Disease
Cymbalta is a selective serotonin and norepinephrine reuptake inhibitor (SSNRI) indicated for the treatment of major depressive disorder, neuropathic pain associated with diabetic peripheral neuropathy, generalized anxiety disorder, fibromyalgia and chronic musculoskeletal pain.
Development timeline for Cymbalta
| Date | Article |
|---|---|
| Nov 5, 2010 | Approval FDA Clears Cymbalta to Treat Chronic Musculoskeletal Pain |
| Nov 30, 2009 | Approval FDA Approves Cymbalta for Maintenance Treatment of Generalized Anxiety Disorder |
| Jun 16, 2008 | Approval FDA Approves Cymbalta for the Management of Fibromyalgia |
| Nov 30, 2007 | Approval FDA Approves Cymbalta for Maintenance Treatment of Major Depressive Disorder |
| Feb 26, 2007 | Approval FDA Approves Cymbalta for Treatment of Generalized Anxiety Disorder |
| Sep 7, 2004 | Approval FDA Approves Cymbalta for Neuropathic Pain Associated With Diabetes |
| Aug 4, 2004 | Approval FDA Approves Cymbalta for the Treatment of Depression |
| Jun 24, 2004 | FDA Extends Action Date for Cymbalta for Continued Analysis of Already-Submitted Data |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
